JP2017510595A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510595A5
JP2017510595A5 JP2016560952A JP2016560952A JP2017510595A5 JP 2017510595 A5 JP2017510595 A5 JP 2017510595A5 JP 2016560952 A JP2016560952 A JP 2016560952A JP 2016560952 A JP2016560952 A JP 2016560952A JP 2017510595 A5 JP2017510595 A5 JP 2017510595A5
Authority
JP
Japan
Prior art keywords
carboxamide
anilino
dihydropyrimido
indolizine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560952A
Other languages
English (en)
Japanese (ja)
Other versions
JP6518690B2 (ja
JP2017510595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/056839 external-priority patent/WO2015155042A1/en
Publication of JP2017510595A publication Critical patent/JP2017510595A/ja
Publication of JP2017510595A5 publication Critical patent/JP2017510595A5/ja
Application granted granted Critical
Publication of JP6518690B2 publication Critical patent/JP6518690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560952A 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン Active JP6518690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207.4 2015-01-30
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
JP2017510595A JP2017510595A (ja) 2017-04-13
JP2017510595A5 true JP2017510595A5 (enExample) 2018-05-17
JP6518690B2 JP6518690B2 (ja) 2019-05-22

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560952A Active JP6518690B2 (ja) 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン

Country Status (16)

Country Link
US (3) USRE50082E1 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
MX376974B (es) * 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
CA3129722A1 (en) 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
MX2024007452A (es) * 2021-12-15 2024-07-09 Sillajen Inc Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.
US20250057844A1 (en) * 2021-12-15 2025-02-20 Sillajen, Inc. Methods of treating neoplastic diseases
EP4447970A4 (en) * 2021-12-15 2025-10-22 Sillajen Inc PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCER
EP4486350A4 (en) * 2022-03-04 2026-01-21 Sillajen Inc PHARMACEUTICAL COMBINATIONS INTENDED FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212760A (pt) * 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
BR122019010200B8 (pt) 2003-05-22 2021-07-27 Nerviano Medical Science S R L compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
EA020703B9 (ru) * 2008-06-26 2015-12-30 Ле Лаборатуар Сервье Пиразолохиназолины
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
ES2553114T3 (es) 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
EP2668190B1 (en) * 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
WO2014209978A1 (en) 2013-06-24 2014-12-31 Merck Patent Gmbh Imidazole compounds as modulators of fshr and uses thereof
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Similar Documents

Publication Publication Date Title
JP2017510595A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CA2934137C (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
JP2015514808A5 (enExample)
EP3555074B1 (en) Aminopyrazoles as selective janus kinase inhibitors
PH12018500765A1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
JP2005539012A5 (enExample)
JP2017502940A5 (enExample)
IL279800B1 (en) Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
JP2019505541A5 (enExample)
JP2021509113A (ja) キナーゼ阻害剤としての複素環式アミド
JP2005538099A5 (enExample)
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
JP2018507877A5 (enExample)
JP2010526129A5 (enExample)
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
EA024406B1 (ru) АМИНОСПИРТ-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ХИНАЗОЛИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
JP2017525668A5 (enExample)
JP2017519781A5 (enExample)
JP2017521407A5 (enExample)
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
JP2015505301A5 (enExample)
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
CA3095233A1 (en) 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.